← IRONWOOD PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | ($81.7m) | ($116.9m) | ($282.4m) | $21.5m | $106.2m | $528.4m | $175.1m | ($1.0b) | $880k | $24.0m | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($81.7m) | ($116.9m) | ($282.4m) | $21.5m | $106.2m | $528.4m | $175.1m | ($1.0b) | $880k | $24.0m | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | ($116.9m) | ($282.4m) | $21.5m | $106.2m | $528.4m | $175.1m | ($1.0b) | $880k | $24.0m | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | $58.9m | $106.2m | $528.4m | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | ($37.4m) | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | ($29.3m) | — | — | |
| Depreciation, Depletion and Amortization | $10.3m | $8.4m | $6.1m | $5.6m | $2.3m | $1.5m | $1.4m | $1.2m | $1.2m | $1.1m | |
| Depreciation | $10.3m | $8.4m | $6.1m | $5.6m | $3.6m | $1.5m | $1.4m | $1.6m | $2.0m | $1.9m | |
| Amortization of Debt Issuance Costs | — | — | — | — | — | $1.7m | $1.9m | — | — | — | |
| Amortization of Debt Issuance Costs and Discounts | $14.8m | $16.1m | $17.6m | $19.6m | $22.3m | $23.9m | $1.9m | $2.1m | $1.9m | — | |
| Amortization of Intangible Assets | $981k | $6.2m | $8.1m | — | — | — | — | — | — | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | ($333.3m) | $65.7m | $72.6m | $68.1m | $40.8m | |
| Share-based Payment Arrangement, Noncash Expense | $29.2m | $33.8m | $44.0m | $31.3m | $31.2m | $22.3m | $27.0m | $32.0m | $29.9m | $17.2m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | — | $737k | — | |
| Share-based Payment Arrangement, Expense | $29.2m | $33.8m | $44.5m | $31.3m | $31.2m | $22.3m | $27.0m | $59.6m | $29.9m | $17.2m | |
| Goodwill, Impairment Loss | — | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| Impairment of Intangible Assets, Finite-lived | — | — | $151.8m | — | — | — | — | — | — | — | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | $0 | $151.8m | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | $204k | ($694k) | $1.9m | ($146k) | ($470k) | ($93k) | ($2k) | — | ($75k) | ($89k) | |
| Gain (Loss) on Extinguishment of Debt | — | ($2.0m) | — | ($31.0m) | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $2.7m | ($327.8m) | $77.4m | $83.5m | $64.3m | $46.0m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $33.0m | $32.7m | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | $640k | $193k | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | — | ($924k) | ($47.2m) | ($35.1m) | |
| Increase (Decrease) in Inventories | — | ($346k) | $806k | — | ($648k) | — | — | — | — | — | |
| Proceeds from Stock Options Exercised | $24.8m | $26.4m | $32.1m | $13.6m | $18.5m | $19.6m | $9.5m | $6.4m | $11.0m | $216k | |
| Gain (Loss) on Sale of Derivatives | — | — | — | $3.0m | — | — | — | — | — | — | |
| Goodwill | $785k | $785k | $785k | $785k | — | — | — | — | — | — | |
| Inventory Write-down | $374k | — | $0 | — | — | — | — | — | — | — | |
| Nonoperating Income (Expense) | ($29.8m) | ($39.6m) | ($43.5m) | ($61.2m) | ($34.1m) | ($31.6m) | $2.1m | ($2.6m) | ($27.9m) | ($28.5m) | |
| Unrealized Gain (Loss) on Derivatives | — | — | ($8.7m) | — | — | — | — | — | — | — | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $8.1m | ($3.3m) | ($8.7m) | $3.0m | ($6.1m) | ($1.2m) | $182k | $19k | — | — | |
| Net Cash Provided by (Used in) Operating Activities | ($25.4m) | ($99.6m) | ($70.9m) | $10.7m | $168.8m | $261.9m | $273.8m | $183.4m | $103.5m | $127.0m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $4.2m | $4.2m | $8.6m | $7.2m | $1.8m | $265k | $136k | $273k | $142k | $34k | |
| Net Cash Provided by (Used in) Investing Activities | ($177.7m) | $151.5m | $88.9m | ($11.1m) | ($1.8m) | ($265k) | ($136k) | ($1.0b) | ($142k) | ($34k) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Long-term Debt | — | $146.2m | — | — | — | — | — | — | — | — | |
| Repayments of Long-term Debt | — | $134.3m | — | — | — | — | — | — | — | — | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | $24.1m | $126.4m | — | — | — | |
| Net Cash Provided by (Used in) Financing Activities | ($4.2m) | $19.8m | $30.1m | ($1.2m) | $18.5m | ($4.5m) | ($237.6m) | $277.2m | ($107.0m) | $216k | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $48.1m | ($1.6m) | $185.5m | $257.1m | $36.1m | ($565.8m) | ($3.6m) | $126.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $180.8m | $179.2m | $364.8m | $621.9m | $657.9m | $92.2m | $88.6m | $215.5m | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $24.5m | $20.4m | $18.2m | $17.6m | $7.2m | $7.2m | $5.7m | $13.6m | $32.6m | $30.3m | |
| Income Taxes Paid, Net | — | — | — | — | $1.8m | $3.5m | $4.6m | $9.9m | $8.4m | $3.5m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.